157 related articles for article (PubMed ID: 20980415)
1. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
Monami M; Colombi C; Balzi D; Dicembrini I; Giannini S; Melani C; Vitale V; Romano D; Barchielli A; Marchionni N; Rotella CM; Mannucci E
Diabetes Care; 2011 Jan; 34(1):129-31. PubMed ID: 20980415
[TBL] [Abstract][Full Text] [Related]
2. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.
Mannucci E; Monami M; Balzi D; Cresci B; Pala L; Melani C; Lamanna C; Bracali I; Bigiarini M; Barchielli A; Marchionni N; Rotella CM
Diabetes Care; 2010 Sep; 33(9):1997-2003. PubMed ID: 20551014
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
[TBL] [Abstract][Full Text] [Related]
4. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
5. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Hamid Z; Simmons DL
Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
[No Abstract] [Full Text] [Related]
6. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
[TBL] [Abstract][Full Text] [Related]
7. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
8. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.
McCall AL; Cox DJ; Brodows R; Crean J; Johns D; Kovatchev B
Diabetes Technol Ther; 2009 Jun; 11(6):339-44. PubMed ID: 19459761
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
11. Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.
Mekuria AN; Ayele Y; Tola A; Mishore KM
J Diabetes Res; 2019; 2019():7676909. PubMed ID: 31828167
[TBL] [Abstract][Full Text] [Related]
12. [Diabetes and cancer risk: oncologic considerations].
Rosta A
Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
[TBL] [Abstract][Full Text] [Related]
13. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.
Bowker SL; Yasui Y; Veugelers P; Johnson JA
Diabetologia; 2010 Aug; 53(8):1631-7. PubMed ID: 20407744
[TBL] [Abstract][Full Text] [Related]
14. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.
van Staa TP; Patel D; Gallagher AM; de Bruin ML
Diabetologia; 2012 Mar; 55(3):654-65. PubMed ID: 22127412
[TBL] [Abstract][Full Text] [Related]
15. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.
Andersson C; Olesen JB; Hansen PR; Weeke P; Norgaard ML; Jørgensen CH; Lange T; Abildstrøm SZ; Schramm TK; Vaag A; Køber L; Torp-Pedersen C; Gislason GH
Diabetologia; 2010 Dec; 53(12):2546-53. PubMed ID: 20838985
[TBL] [Abstract][Full Text] [Related]
16. Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy.
Biondi-Zoccai G; Pinto A; Versaci F; Procaccini E; Neri G; Sesti G; Uccioli L; Vetere M; Peruzzi M; Nudi F
J Cardiovasc Pharmacol; 2016 Aug; 68(2):162-70. PubMed ID: 27074768
[TBL] [Abstract][Full Text] [Related]
17. Antidiabetic Medications and the Risk of Endometrial Cancer in Patients.
Tian J; Liang Y; Qu P
Gynecol Obstet Invest; 2019; 84(5):455-462. PubMed ID: 30808843
[TBL] [Abstract][Full Text] [Related]
18. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
[TBL] [Abstract][Full Text] [Related]
19. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients.
Hirsch IB; Yuan H; Campaigne BN; Tan MH
Endocr Pract; 2009; 15(4):343-8. PubMed ID: 19454394
[TBL] [Abstract][Full Text] [Related]
20. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes.
Johnson M; Krosnick A; Carson P; McDade AM; Laraway K
Clin Ther; 1998; 20(4):691-8. PubMed ID: 9737829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
